As earnings season gains momentum, next week’s slate features heavyweights across tech, energy, industrials, and consumer sectors, offering a broad pulse on corporate health and macro conditions.

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

On a per-share basis, the New York-based company said it had profit of 52 cents. Earnings, adjusted for amortization costs and restructuring costs, were 92 cents per share.

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

Pfizer Inc. (NYSE:PFE) currently pays a quarterly dividend of $0.42 per share and has a dividend yield of 5.64%, as of September 18.